View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 3, 2019

Medtronic’s Attain Stability left heart lead receives FDA approval

The US Food and Drug Administration (FDA) has granted approval to Medtronic’s Attain Stability Quad MRI SureScan left heart lead. The device is the only active-fixation left heart lead, and is designed for precise lead placement and stability.

The US Food and Drug Administration (FDA) has granted approval to Medtronic’s Attain Stability Quad MRI SureScan left heart lead. The device is the only active-fixation left heart lead, and is designed for precise lead placement and stability.

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

Claimed to be the world’s first active fixation left heart lead, the new lead can be combined with Medtronic quadripolar cardiac resynchronisation therapy-defibrillators (CRT-D) and -pacemakers (CRT-P).

Meant for heart failure treatment, cardiac resynchronisation therapy (CRT) involves an implantable device that delivers low levels of energy via thin wires, called leads, to stimulate the heart muscle and enhance pumping efficiency.

Quadripolar leads are intended to allow physicians to pace from various sites in the heart, but are limited in where they can be placed.

“Clinical trial evidence shows this lead is a safe and effective option for patients receiving CRT devices.”

Attain Stability Quad lead is said to integrate the benefits of a quadripolar lead with a side-helix, which allows fixation of the lead precisely in veins of different sizes.

Medtronic noted that the lead can also be placed in veins that are not usually amenable to positioning a passive lead.

Patients implanted with this lead and MR-conditional CRT devices will be able to undergo either 3Tesla (T) and 1.5T magnetic resonance imaging (MRI) scans.

The company is planning to commercially launch the new Attain Stability Quad MRI SureScan left heart lead over the coming months.

Medtronic Cardiac Resynchronization Therapy business vice-president and general manager Kweli Thompson said: “Clinical trial evidence shows this lead is a safe and effective option for patients receiving CRT devices.

“It offers the advantages of established quadripolar leads, while enabling secure placement across various patient anatomies. We are pleased to bring the latest advancement in left-heart lead technology to the US, adding to our diverse portfolio of solutions for patients with heart failure.”

The company’s heart failure portfolio consists of MR-conditional CRT-Ds and CRT-Ps, mechanical circulatory support therapy, heart failure diagnostics and Medtronic Care Management Services.

Related Companies

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network